Walleye Capital’s Ginkgo Bioworks DNA Stock Holding History

Walleye Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,079	Closed	-$42.2K	–	4521
2025 Q4	$42.2K	Buy	+5,079	New	+$54.7K	﹤0.01%	4117
2025 Q1	–	Sell	-266,129	Closed	-$2.61M	–	4418
2024 Q4	$2.61M	Buy	266,129 +248,789	+1,435%	+$2.13M	0.01%	1537
2024 Q3	$141K	Buy	+17,340	New	+$174K	﹤0.01%	4224

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's DNA Position: Q1 2026 in Review

Walleye Capital sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 5,079 shares — an estimated $42.2K sold.

Walleye Capital first reported a position in DNA in Q3 2024 and held it in 3 quarters. The position peaked at $2.61M in Q4 2024. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

Walleye Capital reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 5,079 Ginkgo Bioworks shares in Q1 2026, an estimated $42.2K.
Walleye Capital first reported a position in Ginkgo Bioworks in Q3 2024 and held it in 3 quarters.
Walleye Capital's Ginkgo Bioworks position peaked at $2.61M in Q4 2024.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.